OS 治疗“OST-HER2”药物显示,在防止肺向性骨质瘤复发方面,取得了可喜的成果。 OS Therapies' OST-HER2 drug shows promising results in preventing lung metastatic osteosarcoma recurrence.

OS治疗机构报告说,它们为OST-HER2进行的第2b阶段研究取得了积极成果。 OST-HER2是一种免疫疗法药物,可以防止肺部转移性骨质瘤的复发。 OS Therapies has reported positive outcomes from their Phase 2b study for OST-HER2, an immunotherapy drug for preventing recurrent lung metastatic osteosarcoma. 该研究实现其首要目标,显示33.3%的无意外生存率为12个月,大大高于20%的历史率。 The study met its primary goal, showing a 33.3% event-free survival rate at 12 months, significantly higher than the 20% historical rate. 这一里程碑导致公司在市场前贸易中股票价格上涨50%以上。 This milestone led to a more than 50% increase in the company's stock price in pre-market trading.